BURLINGAME, Calif.--(BUSINESS WIRE)--Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced that the U.S. Food and Drug Administration (FDA) ...
SAN MATEO, Calif. and HONOLULU, Oct. 6, 2025 /PRNewswire/ -- Cala ®, the bioelectronic medicine leader, announced today the publication of a groundbreaking study in the journal Brain Stimulation ...
Cala announced the appointment of Deanna Harshbarger as Chief Executive Officer (CEO) and as a member of the Company's Board of Directors, effective immediately. Concurrently, Cala has appointed ...
- Data are a stark reminder that ET-related healthcare system costs are under-appreciated and underscore the potential of Cala Trio to address the needs of patients and payers - BURLINGAME, ...
A wrist-worn, AI-driven transcutaneous peripheral nerve stimulator is linked to greater improvement in patients with ...
388813 01: A photo illustration depicts a person typing May 4, 2001 in Denver, CO. National Academy of Sciences estimates that musculoskeletal disorders such as carpal-tunnel syndrome, tendinitis, and ...
After securing Medicare coverage for its wearable neurostimulator to help people control their hand tremors, Cala Health has raised $50 million to boost its commercial trajectory. The Silicon ...
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round. Novartis, Baird Capital, LifeSci Venture Partners, TriVentures ...
Editor's note: This article has been updated with a quote from Cala Health's CEO. Calif.-based Cala Health, the maker of wearable neuromodulation therapy, announced that it has completed the initial ...
"I am excited to be serving as the CEO for Cala as we significantly expand access of Cala TAPS Therapy to Medicare patients who represent approximately 75% of the ET population." "It isexciting to see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback